{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:30:43Z","timestamp":1773693043983,"version":"3.50.1"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s10585-012-9517-x","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T08:13:18Z","timestamp":1349770398000},"page":"821-839","source":"Crossref","is-referenced-by-count":38,"title":["Meeting the biologic challenge of colorectal metastases"],"prefix":"10.1007","volume":"29","author":[{"given":"Harold J.","family":"Wanebo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"LeGolvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip B.","family":"Paty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukamal","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael I.","family":"D\u2019Angelica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancey E.","family":"Kemeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,10]]},"reference":[{"key":"9517_CR1","unstructured":"Riles, LAG, Melbert D, Krapcho M et al (2010) SEER Cancer Statistics Review, 1975\u20132005. National Cancer Institute, Bethesda MD, based on November 2007 SEER data submission. Ann Surg Oncol 17:492"},{"key":"9517_CR2","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2002.20.6.1442","volume":"20","author":"B Nordlinger","year":"2002","unstructured":"Nordlinger B, Rougier P (2002) Liver metastases from colorectal cancer: the turning point. J Clin Oncol 20:1442\u20131445","journal-title":"J Clin Oncol"},{"key":"9517_CR3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1245\/s10434-009-0781-1","volume":"17","author":"TC Chua","year":"2010","unstructured":"Chua TC et al (2010) Systematic review of randomized and non randomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17:492\u2013501","journal-title":"Ann Surg Oncol"},{"key":"9517_CR4","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"9517_CR5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. A multicoated randomized trial. Lancet 355:1041\u20131047","journal-title":"Lancet"},{"key":"9517_CR6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23\u201330","journal-title":"J Clin Oncol"},{"key":"9517_CR7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C et al (2009) Fluorouracil, leucovorin and oxaliplatin with and without Cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663\u2013671","journal-title":"J Clin Oncol"},{"key":"9517_CR8","first-page":"2335","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H et al (2004) Bevacizumab in combination with Oxaliplatin-cancer. A randomized phase III study. J Clin Oncol 350:2335\u20132342","journal-title":"J Clin Oncol"},{"key":"9517_CR9","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB et al (2008) Bevacizumab in combination with Oxaliplatin based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019","journal-title":"J Clin Oncol"},{"key":"9517_CR10","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/jso.21691","volume":"102","author":"H Wanebo","year":"2010","unstructured":"Wanebo H, Berz D (2010) Neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors. J Surg Oncol 102:891\u2013897","journal-title":"J Surg Oncol"},{"key":"9517_CR11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10434-001-0347-3","volume":"8","author":"R Adam","year":"2001","unstructured":"Adam R et al (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347\u2013353","journal-title":"Ann Surg Oncol"},{"key":"9517_CR12","doi-asserted-by":"crossref","unstructured":"Adam R et al (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052\u20131061; discussion 1061\u20131064","DOI":"10.1097\/01.sla.0000145964.08365.01"},{"key":"9517_CR13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","volume":"371","author":"B Nordlinger","year":"2008","unstructured":"Nordlinger B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 371:1007\u20131016","journal-title":"Lancet"},{"key":"9517_CR14","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2007.13.7471","volume":"26","author":"R Adam","year":"2008","unstructured":"Adam R et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26:1635\u20131641","journal-title":"J Clin Oncol"},{"key":"9517_CR15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2407-8-120","volume":"8","author":"B Gruenberger","year":"2008","unstructured":"Gruenberger B et al (2008) Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8:120","journal-title":"BMC Cancer"},{"key":"9517_CR16","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1200\/JCO.2008.17.5299","volume":"26","author":"DG Blazer III","year":"2008","unstructured":"Blazer DG III et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26:5344\u20135351","journal-title":"J Clin Oncol"},{"key":"9517_CR17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273\u2013286","journal-title":"Nat Rev Drug Discov"},{"key":"9517_CR18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson AK et al (2006) VEGF receptor signaling\u2014in control of vascular function. Nat Rev Mol Cell Biol 7:359\u2013371","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9517_CR19","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","volume":"23","author":"HI Hurwitz","year":"2005","unstructured":"Hurwitz HI et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regiment for first line metastatic colorectal cancer. J Clin Oncol 23:3502\u20133508","journal-title":"J Clin Oncol"},{"key":"9517_CR20","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","volume":"20","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E et al (2009) Safety and efficacy of first-line Bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer. The BEAT study. Ann Oncol 20:1842\u20131847","journal-title":"Ann Oncol"},{"key":"9517_CR21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.clinthera.2010.03.012","volume":"32","author":"J Tol","year":"2010","unstructured":"Tol J, Punt CJ (2010) Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 32:437\u2013453","journal-title":"Clin Ther"},{"key":"9517_CR22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D et al (2004) Cetuximab monotherapy and Cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337\u2013345","journal-title":"N Engl J Med"},{"key":"9517_CR23","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Lang I, D\u2019haens G et al (2008) KRAS stats on efficacy in the first-line treatment of patient with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without Cetuximab: the CRYSTAL experience. J Clin Oncol 26:abstr. 2","DOI":"10.1200\/jco.2008.26.15_suppl.2"},{"key":"9517_CR24","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408\u20131417","journal-title":"N Engl J Med"},{"key":"9517_CR25","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","volume":"28","author":"A Bardelli","year":"2010","unstructured":"Bardelli A, Siena S (2010) Molecular mechanisms of resistance in Cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254\u20131261","journal-title":"J Clin Oncol"},{"key":"9517_CR26","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/0008-5472.CAN-08-2466","volume":"69","author":"A Sartore-Bianchi","year":"2009","unstructured":"Sartore-Bianchi A et al (2009) P1K3CA mutations in colorectal cancer are associated with clinical resistance to EGFR targeted monoclonal antibodies. Cancer Res 69:1851\u20131857","journal-title":"Cancer Res"},{"key":"9517_CR27","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1200\/JCO.2008.21.6796","volume":"27","author":"P Laurent-Puig","year":"2009","unstructured":"Laurent-Puig P et al (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from Cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924\u20135930","journal-title":"J Clin Oncol"},{"key":"9517_CR28","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1200\/JCO.2006.10.5437","volume":"25","author":"S Khambata-Ford","year":"2007","unstructured":"Khambata-Ford S et al (2007) Expression of epiregulin and amphineegulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with Cetuximab. J Clin Oncol 25:3230\u20133237","journal-title":"J Clin Oncol"},{"key":"9517_CR29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/jso.21817","volume":"102","author":"MP LeGolvan","year":"2010","unstructured":"LeGolvan MP, Resnick M (2010) Pathobiology of colorectal hepatic metastases with an emphasis on prognostic factors. JSO 102:898\u2013908","journal-title":"JSO"},{"key":"9517_CR30","first-page":"293","volume":"1796","author":"TR Geiger","year":"2009","unstructured":"Geiger TR, Peeper DS (2009) Metastasis mechanisms. Biochim Biophys Acta 1796:293\u2013308","journal-title":"Biochim Biophys Acta"},{"key":"9517_CR31","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial\u2013mesenchymal transitions in development and disease. Cell 139:871\u2013890","journal-title":"Cell"},{"key":"9517_CR32","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1038\/sj.onc.1206887","volume":"22","author":"M Jechlinger","year":"2003","unstructured":"Jechlinger M, Grunert S, Tamir IH et al (2003) Expression profiling of epithelial plasticity in tumor progression. Oncogene 22:7155\u20137169","journal-title":"Oncogene"},{"key":"9517_CR33","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1053\/j.gastro.2006.06.016","volume":"131","author":"S Spaderna","year":"2006","unstructured":"Spaderna S, Schmalhofer O, Hlubek F et al (2006) A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131:830\u2013840","journal-title":"Gastroenterology"},{"key":"9517_CR34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ijc.1539","volume":"94","author":"J Lohi","year":"2001","unstructured":"Lohi J (2001) Laminin-5 in the progression of carcinomas. J Int Cancer 94:763\u2013767","journal-title":"J Int Cancer"},{"key":"9517_CR35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/1097-0215(20001201)88:5<708::AID-IJC5>3.0.CO;2-J","volume":"88","author":"I Sordat","year":"2000","unstructured":"Sordat I, Rousselle P, Chaubert P et al (2000) Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer 88:708\u2013717","journal-title":"Int J Cancer"},{"key":"9517_CR36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.matbio.2009.07.008","volume":"28","author":"CM Guess","year":"2009","unstructured":"Guess CM, Quaranta V (2009) Defining the role of laminin-332 in carcinoma. Matrix Biol 28:445\u2013455","journal-title":"Matrix Biol"},{"key":"9517_CR37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1349-7006.2006.00150.x","volume":"97","author":"K Miyazaki","year":"2006","unstructured":"Miyazaki K (2006) Laminin-5 (laminin-332): unique biological activity and role in tumor growth and invasion. Cancer Sci 97:91\u201398","journal-title":"Cancer Sci"},{"key":"9517_CR38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1582-4934.2009.00852.x","volume":"14","author":"KA Paschos","year":"2010","unstructured":"Paschos KA, Canovas D, Bird NC (2010) The engagement of selectins and their ligands in colorectal cancer liver metastases. J Cell Mol Med 14:165\u2013174","journal-title":"J Cell Mol Med"},{"key":"9517_CR39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cellsig.2009.01.006","volume":"21","author":"KA Paschos","year":"2009","unstructured":"Paschos KA, Canovas D, Bird NC (2009) The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 21:665\u2013674","journal-title":"Cell Signal"},{"key":"9517_CR40","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/bjc.1995.119","volume":"71","author":"S Dorudi","year":"1995","unstructured":"Dorudi S, Hanby AM, Poulsom R et al (1995) Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 71:614\u2013616","journal-title":"Br J Cancer"},{"key":"9517_CR41","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s10517-005-0385-0","volume":"139","author":"VV Delektorskaya","year":"2005","unstructured":"Delektorskaya VV, Perevoshchikov AG, Golovkov DA, Kushlinskii NE (2005) Expression of E-cadherin, beta-catenin, and CD-44v6 cell adhesion molecules in primary tumors and metastases of colorectal adenocarcinoma. Bull Exp Biol Med 139:706\u2013710","journal-title":"Bull Exp Biol Med"},{"key":"9517_CR42","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.clon.2006.08.007","volume":"18","author":"SA Han","year":"2006","unstructured":"Han SA, Chun H, Park CM et al (2006) Prognostic significance of beta-catenin in colorectal cancer with liver metastasis. Clin Oncol 18:761\u2013767","journal-title":"Clin Oncol"},{"key":"9517_CR43","first-page":"1821","volume":"28","author":"H Suzuki","year":"2008","unstructured":"Suzuki H, Masuda N, Shimura T et al (2008) Nuclear beta-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res 28:1821\u20131830","journal-title":"Anticancer Res"},{"key":"9517_CR44","first-page":"57","volume":"21","author":"HN Choi","year":"2009","unstructured":"Choi HN, Kim KR, Lee JH et al (2009) Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin\/beta\u2013catenin complex. Oncol Rep 21:57\u201363","journal-title":"Oncol Rep"},{"key":"9517_CR45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00441-009-0834-6","volume":"339","author":"M Barczyk","year":"2010","unstructured":"Barczyk M, Carracedo S, Gullberg D (2010) Integrins. Cell Tissue Res 339:269\u2013280","journal-title":"Cell Tissue Res"},{"key":"9517_CR46","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2174\/138161208783413284","volume":"14","author":"JH Robertson","year":"2008","unstructured":"Robertson JH, Iga AM, Sales KM et al (2008) Integrins: a method of early intervention in the treatment of colorectal liver metastases. Curr Pharm Des 14:296\u2013305","journal-title":"Curr Pharm Des"},{"key":"9517_CR47","first-page":"741","volume":"138","author":"K Koretz","year":"1991","unstructured":"Koretz K, Schlag P, Boumsell L, M\u00f6ller P (1991) Expression of VLA-alpha 2, VLA-alpha 6, and VLA-beta 1 chains in normal mucosa and adenomas of the colon, and in colon carcinomas and their liver metastases. Am J Pathol 138:741\u2013750","journal-title":"Am J Pathol"},{"key":"9517_CR48","first-page":"83","volume":"8","author":"J Gong","year":"1997","unstructured":"Gong J, Wang D, Sun L et al (1997) Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ 8:83\u201390","journal-title":"Cell Growth Differ"},{"key":"9517_CR49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","volume":"92","author":"R Visse","year":"2003","unstructured":"Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827\u2013839","journal-title":"Circ Res"},{"key":"9517_CR50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1025867130437","volume":"23","author":"S Zucker","year":"2004","unstructured":"Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23:101\u2013117","journal-title":"Cancer Metastasis Rev"},{"key":"9517_CR51","first-page":"3387","volume":"25","author":"M Pesta","year":"2005","unstructured":"Pesta M, Holubec L, Topolcan O et al (2005) Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25:3387\u20133391","journal-title":"Anticancer Res"},{"key":"9517_CR52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-540-46091-6_7","volume":"176","author":"U Stein","year":"2007","unstructured":"Stein U, Schlag PM (2007) Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 176:61\u201380","journal-title":"Recent Results Cancer Res"},{"key":"9517_CR53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jso.20393","volume":"92","author":"LR Rudmik","year":"2005","unstructured":"Rudmik LR, Magliocco AM (2005) Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 92:347\u2013359","journal-title":"J Surg Oncol"},{"key":"9517_CR54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10517-007-0155-2","volume":"143","author":"VV Delektorskaya","year":"2007","unstructured":"Delektorskaya VV, Perevoshchikov AG, Golovkov DA, Kushlinskii NE (2007) Prognostic significance of expression of matrix metalloproteinase in colorectal adenocarcinomas and their metastases. Bull Exp Biol Med 143:455\u2013458","journal-title":"Bull Exp Biol Med"},{"key":"9517_CR55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10517-009-0507-1","volume":"147","author":"DA Golovkov","year":"2009","unstructured":"Golovkov DA (2009) Key enzymes of the extracellular matrix in colorectal cancer. Bull Exp Biol Med 147:353\u2013356","journal-title":"Bull Exp Biol Med"},{"key":"9517_CR56","first-page":"67","volume":"29","author":"B Gentner","year":"2009","unstructured":"Gentner B, Wein A, Croner RS et al (2009) Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res 29:67\u201374","journal-title":"Anticancer Res"},{"key":"9517_CR57","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/ijc.24166","volume":"124","author":"M Illemann","year":"2009","unstructured":"Illemann M, Bird N, Majeed A et al (2009) Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 124:1860\u20131870","journal-title":"Int J Cancer"},{"key":"9517_CR58","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0002-9440(10)64632-9","volume":"157","author":"Y Friedmann","year":"2000","unstructured":"Friedmann Y, Vlodavsky I, Aingorn H et al (2000) Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 157:1167\u20131175","journal-title":"Am J Pathol"},{"key":"9517_CR59","first-page":"147","volume":"1","author":"MF Renzo Di","year":"1995","unstructured":"Di Renzo MF, Olivero M, Giacomini A et al (1995) Overexpression and amplification of the met\/HGF receptor gene during the progression of colorectal cancer. Clinical Cancer Res 1:147\u2013154","journal-title":"Clinical Cancer Res"},{"key":"9517_CR60","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1024024218529","volume":"20","author":"MH Herynk","year":"2003","unstructured":"Herynk MH, Tsan R, Radinsky R, Gallick GE (2003) Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis 20:291\u2013300","journal-title":"Clin Exp Metastasis"},{"key":"9517_CR61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nm.1889","volume":"15","author":"U Stein","year":"2009","unstructured":"Stein U, Walther W, Arlt F et al (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15:59\u201367","journal-title":"Nat Med"},{"key":"9517_CR62","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/jnci\/djp280","volume":"101","author":"S Siena","year":"2009","unstructured":"Siena S, Sartore-Bianchi A, Di Nicolantonio F et al (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308\u20131324","journal-title":"J Natl Cancer Inst"},{"key":"9517_CR63","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-07-4499","volume":"14","author":"M Yamada","year":"2008","unstructured":"Yamada M, Ichikawa Y, Yamagishi S et al (2008) Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clinical Cancer Res 14:2351\u20132356","journal-title":"Clinical Cancer Res"},{"key":"9517_CR64","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4161\/mabs.2.2.11360","volume":"2","author":"LA Sullivan","year":"2010","unstructured":"Sullivan LA, Brekken RA (2010) The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2:165\u2013175","journal-title":"MAbs"},{"key":"9517_CR65","first-page":"973","volume":"18","author":"CR Berney","year":"1998","unstructured":"Berney CR, Yang JL, Fisher RJ et al (1998) Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Anticancer Res 18:973\u2013977","journal-title":"Anticancer Res"},{"key":"9517_CR66","first-page":"373","volume":"5","author":"K Maeda","year":"2000","unstructured":"Maeda K, Nishiguchi Y, Yashiro M et al (2000) Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 5:373\u2013378","journal-title":"Int J Mol Med"},{"key":"9517_CR67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10456-009-9147-3","volume":"12","author":"M Thomas","year":"2009","unstructured":"Thomas M, Augustin H (2009) The role of the angiopoietins in vascular morphogenesis. Angiogenesis 12:125\u2013137","journal-title":"Angiogenesis"},{"key":"9517_CR68","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/1097-0142(20010901)92:5<1138::AID-CNCR1431>3.0.CO;2-L","volume":"92","author":"SA Ahmad","year":"2001","unstructured":"Ahmad SA, Liu W, Jung YD et al (2001) Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 92:1138\u20131143","journal-title":"Cancer"},{"key":"9517_CR69","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jso.20423","volume":"94","author":"YC Chung","year":"2006","unstructured":"Chung YC, Hou YC, Chang CN, Hseu TH (2006) Expression and prognostic significance of angiopoietin in colorectal carcinoma. J Surg Oncol 94:631\u2013638","journal-title":"J Surg Oncol"},{"key":"9517_CR70","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1056\/NEJMra0804588","volume":"361","author":"SD Markowitz","year":"2009","unstructured":"Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. New Engl J Med 361:2449\u20132460","journal-title":"New Engl J Med"},{"key":"9517_CR71","first-page":"647","volume":"11","author":"W Kastrinakis","year":"1995","unstructured":"Kastrinakis W, Ramchurren N, Rieger K et al (1995) Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 11:647\u2013652","journal-title":"Oncogene"},{"key":"9517_CR72","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0959-8049(97)00118-4","volume":"33","author":"I Heide","year":"1997","unstructured":"Heide I, Thiede C, Sonntag T et al (1997) The status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer 33:1314\u20131322","journal-title":"Eur J Cancer"},{"key":"9517_CR73","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mc.2940130306","volume":"13","author":"S Peller","year":"1995","unstructured":"Peller S, Halevy A, Slutzki S et al (1995) p53 mutations in matched primary and metastatic human tumors. Mol Carcinog 13:166\u2013172","journal-title":"Mol Carcinog"},{"key":"9517_CR74","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1158\/1078-0432.CCR-04-2389","volume":"11","author":"KP Jong de","year":"2005","unstructured":"de Jong KP, Gouw AS, Peeters PM et al (2005) P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res 11:4067\u20134073","journal-title":"Clin Cancer Res"},{"key":"9517_CR75","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2006.03.007","volume":"244","author":"NK Sah","year":"2006","unstructured":"Sah NK, Khan Z, Khan GJ, Bisen PS (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244:164\u2013171","journal-title":"Cancer Lett"},{"key":"9517_CR76","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00384-009-0725-z","volume":"24","author":"Y Fang","year":"2009","unstructured":"Fang Y, Lu Z, Wang G et al (2009) Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 24:875\u2013884","journal-title":"Int J Colorectal Dis"},{"key":"9517_CR77","doi-asserted-by":"crossref","unstructured":"Viehl CT, Guller U, Cecini R, Langer I, Ochsner A, Terracciano L, Riehle HM, Laffer U, Oertli D, Zuber M (2011) Sentinel lymph node procedure leads to upstaging of patients with resectable colon cancer. Results of the Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer. Ann Surg Oncol 2011; published online 10 February 2012. doi: 10.1245\/s10434-012-2233-6","DOI":"10.1245\/s10434-012-2233-6"},{"key":"9517_CR78","first-page":"215","volume":"105","author":"T Notomi","year":"2000","unstructured":"Notomi T, Okayama H, Masubuchi H et al (2000) Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 105:215\u2013222","journal-title":"Nucleic Acids Res"},{"key":"9517_CR79","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-06-2512","volume":"13","author":"M Tsujimoto","year":"2007","unstructured":"Tsujimoto M, Nakabayashi K, Yoshidome K et al (2007) One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13:4807\u20134816","journal-title":"Clin Cancer Res"},{"key":"9517_CR80","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1002\/cncr.26060","volume":"117","author":"T Osako","year":"2011","unstructured":"Osako T, Iwase T, Kimura K et al (2011) Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: a comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology. Cancer 117:4365\u20134374","journal-title":"Cancer"},{"key":"9517_CR81","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1158\/1078-0432.CCR-08-1881","volume":"15","author":"Y Tamaki","year":"2009","unstructured":"Tamaki Y, Akiyama F, Iwase T et al (2009) Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res 15:2879\u20132884","journal-title":"Clin Cancer Res"},{"key":"9517_CR82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1479-5876-8-83","volume":"8","author":"RS Croner","year":"2010","unstructured":"Croner RS, Schellerer V, Demund H et al (2010) One step nucleic acid amplification (OSNA)\u2014a new method for lymph node staging in colorectal carcinomas. J Transl Med 8:83","journal-title":"J Transl Med"},{"key":"9517_CR83","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1245\/s10434-010-1539-5","volume":"18","author":"H Yamamoto","year":"2011","unstructured":"Yamamoto H, Sekimoto M, Oya M et al (2011) OSNA-based novel molecular testing for lymph node metastases in colorectal cancer patients: results from a multicenter clinical performance study in Japan. Ann Surg Oncol 18:1891\u20131898","journal-title":"Ann Surg Oncol"},{"key":"9517_CR84","doi-asserted-by":"crossref","unstructured":"Guller U, Zettl A, Worni M, Langer I, Cabalzar-Wondberg D, Viehl CT, Demartines N, Zuber M (2012) Molecular investigation of lymph nodes in colon cancer patients using one-step nucleic acid amplification (OSNA): a new road to better staging? Cancer; accepted for publication","DOI":"10.1002\/cncr.27667"},{"issue":"8","key":"9517_CR85","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/jso.21720","volume":"102","author":"FG Rocha","year":"2010","unstructured":"Rocha FG, D\u2019Angelica M (2010) Treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, and microwave coagulation. J Surg Oncol 102(8):968\u2013974","journal-title":"J Surg Oncol"},{"issue":"11","key":"9517_CR86","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/bjs.1800771115","volume":"77","author":"J Scheele","year":"1990","unstructured":"Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77(11):1241\u20131246","journal-title":"Br J Surg"},{"issue":"7","key":"9517_CR87","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/sj.bjc.6603033","volume":"94","author":"PC Simmonds","year":"2006","unstructured":"Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94(7):982\u2013999","journal-title":"Br J Cancer"},{"issue":"9","key":"9517_CR88","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archsurg.1989.01410090027004","volume":"124","author":"W Silen","year":"1989","unstructured":"Silen W (1989) Hepatic resection for metastases from colorectal carcinoma is of dubious value. Arch Surg 124(9):1021\u20131022","journal-title":"Arch Surg"},{"issue":"29","key":"9517_CR89","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","volume":"25","author":"JS Tomlinson","year":"2007","unstructured":"Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D\u2019Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575\u20134580","journal-title":"J Clin Oncol"},{"issue":"2","key":"9517_CR90","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/j.seminoncol.2011.01.001","volume":"38","author":"DV Catenacci","year":"2011","unstructured":"Catenacci DV, Kozloff M, Kindler HL, Polite B (2011) Personalized colon cancer care in 2010. Semin Oncol 38(2):284\u2013308","journal-title":"Semin Oncol"},{"issue":"3","key":"9517_CR91","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309\u2013318","journal-title":"Ann Surg"},{"key":"9517_CR92","doi-asserted-by":"crossref","unstructured":"House MG, Ito H, G\u00f6nen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D\u2019Angelica MI (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 210(5):744\u2013752, 752\u2013755","DOI":"10.1016\/j.jamcollsurg.2009.12.040"},{"issue":"1","key":"9517_CR93","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/SLA.0b013e3181557e47","volume":"247","author":"JS Gold","year":"2008","unstructured":"Gold JS, Are C, Kornprat P, Jarnagin WR, G\u00f6nen M, Fong Y, DeMatteo RP, Blumgart LH, D\u2019Angelica M (2008) Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg 247(1):109\u2013117","journal-title":"Ann Surg"},{"issue":"8","key":"9517_CR94","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1200\/JCO.2010.32.6132","volume":"29","author":"A Brouquet","year":"2011","unstructured":"Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN (2011) High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083\u20131090","journal-title":"J Clin Oncol"},{"issue":"9","key":"9517_CR95","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/bjs.1800730917","volume":"73","author":"H Ekberg","year":"1986","unstructured":"Ekberg H, Tranberg KG, Andersson R, Lundstedt C, H\u00e4gerstrand I, Ranstam J, Bengmark S (1986) Determinants of survival in liver resection for colorectal secondaries. Br J Surg 73(9):727\u2013731","journal-title":"Br J Surg"},{"issue":"11","key":"9517_CR96","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1245\/ASO.2005.01.010","volume":"12","author":"D Elias","year":"2005","unstructured":"Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, Malka D, Pignon JP, Lasser P (2005) Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 12(11):900\u2013909","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"9517_CR97","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1245\/s10434-009-0521-6","volume":"16","author":"DR Carpizo","year":"2009","unstructured":"Carpizo DR, Are C, Jarnagin W, Dematteo R, Fong Y, G\u00f6nen M, Blumgart L, D\u2019Angelica M (2009) Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol 16(8):2138\u20132146","journal-title":"Ann Surg Oncol"},{"key":"9517_CR98","doi-asserted-by":"crossref","unstructured":"Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240(6):1052\u20131061","DOI":"10.1097\/01.sla.0000145964.08365.01"},{"issue":"2","key":"9517_CR99","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.gassur.2005.07.027","volume":"10","author":"TM Pawlik","year":"2006","unstructured":"Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA (2006) Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg 10(2):240\u2013248","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"9517_CR100","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1245\/s10434-006-9068-y","volume":"14","author":"P Kornprat","year":"2007","unstructured":"Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D\u2019Angelica M (2007) Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 14(3):1151\u20131160","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"9517_CR101","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/01.sla.0000160703.75808.7d","volume":"241","author":"TM Pawlik","year":"2005","unstructured":"Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241(5):715\u2013722","journal-title":"Ann Surg"},{"issue":"2","key":"9517_CR102","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/SLA.0b013e31811ea962","volume":"246","author":"C Are","year":"2007","unstructured":"Are C, Gonen M, Zazzali K, Dematteo RP, Jarnagin WR, Fong Y, Blumgart LH, D\u2019Angelica M (2007) The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg 246(2):295\u2013300","journal-title":"Ann Surg"},{"key":"9517_CR103","unstructured":"American Cancer Society (2011) Cancer facts & figures\u00a02011. American Cancer Society, Atlanta"},{"key":"9517_CR104","unstructured":"Kemeny, N.E., Kemeny, M. M., Lawrence, T.S., Liver Metastases, in Clinical Oncology, M.D. Abeloff, Armitage, J., Niederhuber, J., Kastan, M., McKenna, W.G., Editor. 2004, Elsevier: Philadelphia"},{"key":"9517_CR105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/path.1711500308","volume":"150","author":"L Weiss","year":"1986","unstructured":"Weiss L, Grandmann E, Torhost J et al (1986) Hematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 150:195\u2013203","journal-title":"J Pathol"},{"key":"9517_CR106","first-page":"77","volume":"2","author":"L Weiss","year":"1989","unstructured":"Weiss L (1989) Metastatic inefficiency and regional therapy for liver metastases from colorectal carcinoma. Regul Cancer Treat 2:77\u201381","journal-title":"Regul Cancer Treat"},{"issue":"5","key":"9517_CR107","first-page":"969","volume":"30","author":"C Breedis","year":"1954","unstructured":"Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30(5):969\u2013977","journal-title":"Am J Pathol"},{"key":"9517_CR108","unstructured":"Ackerman NB (1974) The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 75(4):589\u2013596"},{"issue":"11","key":"9517_CR109","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.1987.5.11.1836","volume":"5","author":"ER Sigurdson","year":"1987","unstructured":"Sigurdson ER et al (1987) Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 5(11):1836\u20131840","journal-title":"J Clin Oncol"},{"issue":"2","key":"9517_CR110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/sonc.2002.31679","volume":"29","author":"WD Ensminger","year":"2002","unstructured":"Ensminger WD (2002) Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 29(2):119\u2013125","journal-title":"Semin Oncol"},{"issue":"2","key":"9517_CR111","first-page":"176","volume":"10","author":"WD Ensminger","year":"1983","unstructured":"Ensminger WD, Gyves JW (1983) Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10(2):176\u2013182","journal-title":"Semin Oncol"},{"issue":"5","key":"9517_CR112","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.1984.2.5.498","volume":"2","author":"JM McCollins","year":"1984","unstructured":"McCollins JM (1984) Pharmacologic rationale for regional drug delivery. J Clin Oncol 2(5):498\u2013504","journal-title":"J Clin Oncol"},{"key":"9517_CR113","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/978-3-642-82635-1_18","volume":"100","author":"JM Collins","year":"1986","unstructured":"Collins JM (1986) Pharmacologic rationale for hepatic arterial therapy. Recent Results Cancer Res 100:140\u2013147","journal-title":"Recent Results Cancer Res"},{"key":"9517_CR114","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.cad.0000131684.06390.fe","volume":"15","author":"R Rodic","year":"2004","unstructured":"Rodic R, Gomez-Abuin G, Rougier P et al (2004) Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs 15:647\u2013650","journal-title":"Anticancer Drugs"},{"key":"9517_CR115","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.2005.05.120","volume":"23","author":"M Ducreux","year":"2005","unstructured":"Ducreux M, Ychou M, Laplanche A et al (2005) Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23:4881\u20134887","journal-title":"J Clin Oncol"},{"key":"9517_CR116","first-page":"405","volume":"8","author":"JMGH Riel Van","year":"2004","unstructured":"Van Riel JMGH, Van Groeningen C, Kedde M et al (2004) Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 8:405\u2013412","journal-title":"Clin Cancer Res"},{"key":"9517_CR117","first-page":"118","volume":"73","author":"R Tandon","year":"1973","unstructured":"Tandon R, Bunnell I, Copper R (1973) The treatment of metastatic carcinoma of the liver by percutaneous selective hepatic artery infusion of 5-fluorouracil. Surgery 73:118","journal-title":"Surgery"},{"key":"9517_CR118","first-page":"393","volume":"65","author":"W Ensminer","year":"1981","unstructured":"Ensminer W, Niederhuber J, Dakhil S, Thrall J, Wheeler R (1981) Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 65:393\u2013400","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"9517_CR119","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1158\/1535-7163.MCT-08-0709","volume":"8","author":"DG Power","year":"2009","unstructured":"Power DG, Kemeny NE (2009) The role of floxuridine in metastatic liver disease. Mol Cancer Ther 8(5):1015\u20131025","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"9517_CR120","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","volume":"24","author":"N Kemeny","year":"2006","unstructured":"Kemeny N et al (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24(9):1395\u20131403","journal-title":"J Clin Oncol"},{"key":"9517_CR121","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1200\/JCO.2007.12.1764","volume":"25","author":"S Mocellin","year":"2007","unstructured":"Mocellin S, Pilati P, Lise M et al (2007) Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 25:5649\u20135654","journal-title":"J Clin Oncol"},{"key":"9517_CR122","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jamcollsurg.2005.03.019","volume":"201","author":"PJ Allen","year":"2005","unstructured":"Allen PJ, Nissan A, Picon AI et al (2005) Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 201:57\u201365","journal-title":"J Am Coll Surg"},{"key":"9517_CR123","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/bjs.1800660603","volume":"66","author":"J Northover","year":"1979","unstructured":"Northover J, Terblance J (1979) A new look at the arterial supply of the bile duct in man and its surgical implications. Br J Surg 66:379\u2013384","journal-title":"Br J Surg"},{"key":"9517_CR124","unstructured":"Kemeny N (1992) Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes! In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology, chap 12. J.B. Lippincott Co., New York, pp 207\u2013228"},{"key":"9517_CR125","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2008.17.3781","volume":"26","author":"E Mitry","year":"2008","unstructured":"Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:4906\u20134911","journal-title":"J Clin Oncol"},{"issue":"13","key":"9517_CR126","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1200\/JCO.2009.26.9340","volume":"28","author":"DG Power","year":"2010","unstructured":"Power DG, Kemeny NE (2010) The role of adjuvant therapy after resection of colorectal cancer liver-metastases. J Clin Oncol 28(13):2300\u20132309","journal-title":"J Clin Oncol"},{"issue":"27","key":"9517_CR127","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJM199912303412702","volume":"341","author":"N Kemeny","year":"1999","unstructured":"Kemeny N, Huang Y, Cohen AM et al (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341(27):2039","journal-title":"N Engl J Med"},{"issue":"7","key":"9517_CR128","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM200502173520723","volume":"352","author":"NE Kemeny","year":"2005","unstructured":"Kemeny NE, Gonen M (2005) Hepatic arterial infusion after liver resection [7]. N Engl J Med 352(7):734\u2013735","journal-title":"N Engl J Med"},{"issue":"6","key":"9517_CR129","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.20.6.1499","volume":"20","author":"MM Kemeny","year":"2002","unstructured":"Kemeny MM, Adak S, Gray B et al (2002) Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy\u2014an intergroup study. J Clin Oncol 20(6):1499\u20131505","journal-title":"J Clin Oncol"},{"issue":"42","key":"9517_CR130","first-page":"1685","volume":"48","author":"NJ Lygidakis","year":"2001","unstructured":"Lygidakis NJ, Sgourakis G, Vlachos L et al (2001) Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 48(42):1685\u20131691","journal-title":"Hepatogastroenterology"},{"issue":"6","key":"9517_CR131","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00000658-199812000-00006","volume":"228","author":"M Lorenz","year":"1998","unstructured":"Lorenz M, Muller HH, Schramm H et al (1998) Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228(6):756\u2013762","journal-title":"Ann Surg"},{"key":"9517_CR132","doi-asserted-by":"crossref","unstructured":"Kemeny NE, Jarnagin W, Gonen M et al (2005) Phase I trial of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) in combination with systemic oxaliplatin (OXAL), fluorouracil (FU)\u00a0+\u00a0leucovorin (LV) after resection of hepatic metastases from colorectal cancer. J Clin Oncol 23(16S):Abstract No: 3579","DOI":"10.1200\/jco.2005.23.16_suppl.3579"},{"key":"9517_CR133","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2010.32.5977","volume":"29","author":"NE Kemeny","year":"2011","unstructured":"Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, Dematteo RP (2011) D\u2019Angelica MI Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol 29:884\u2013889","journal-title":"J Clin Oncol"},{"issue":"6","key":"9517_CR134","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/SLA.0b013e31822f4f88","volume":"254","author":"MG House","year":"2011","unstructured":"House MG, Kemeny NE, Gonen M, Fong Y, Allen PJ, Paty PB, DeMatteo RP, Blumgart LH, Jarnagin WR, D\u2019Angelica MI (2011) Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg 254(6):851\u2013856","journal-title":"Ann Surg"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-012-9517-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-012-9517-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-012-9517-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T10:37:31Z","timestamp":1562236651000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-012-9517-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":134,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["9517"],"URL":"https:\/\/doi.org\/10.1007\/s10585-012-9517-x","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}